An observational study in Glioma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Memorial Sloan Kettering Cancer Center · Observational
Among 22 studies in Glioma by Memorial Sloan Kettering Cancer Center — 5 open to participants now, 7 under way, none of them phase 3. Glioma · Memorial Sloan Kettering Cancer Center.
Among the 22 studies in Glioma by Memorial Sloan Kettering Cancer Center, this one is one of 2 that started in 2022, is one of 3 observational ones, and was the 19th registered.
1,452 studies on the registry are indexed under Glioma; 349 are open to participants now.
This study's planned enrollment of 50 is below the median of 90 across 273 observational studies indexed under Glioma.
Browse Glioma studies →5 of the 22 studies in Glioma by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Each count lists the studies.
Of the 267 Glioma studies recruiting now, 164 (61%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →22 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2022.
Median enrollment 27 across the 15 interventional studies, 50 across the 3 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 327 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
6 of the studies in Glioma by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02658279Memorial Sloan Kettering Cancer CenterPembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype | 2027-01 |
| NCT05188508Memorial Sloan Kettering Cancer CenterPembrolizumab, Olaparib, and Temozolomide for People With Glioma | 2027-01 |
| NCT06209567Memorial Sloan Kettering Cancer CenterA Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors | 2027-01-05 |
| NCT05489783Memorial Sloan Kettering Cancer CenterGlioma Developmental and HyperActive Ras Tumor (DHART) Board | 2027-07-31 |
| NCT00870129Memorial Sloan Kettering Cancer CenterMagnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors | 2027-09 |
Among the 22 studies in Glioma by Memorial Sloan Kettering Cancer Center, from their registry updates:
This study will collect medical records, scan results, and complete surveys to create a registry about people with a neurofibromatosis type 1-associated brain tumor (NF1-associated glioma). A registry is a collection of health information about individuals, and it is usually focused on a specific diagnosis or condition.
This registry study will help the researchers learn more about the diagnosis, treatment, and quality of life of people with NF1-associated glioma. The researchers want to understand what happens as a result of different treatments for NF1-associated glioma and how these treatments and the disease itself affect people's lives over a period of time. Information collected during this study could affect how doctors diagnose, test, and treat NF1-associated glioma, and the study could help future patients with this type of cancer.
Patients with NF1 glioma will be enrolled in this registry study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Registry of patients with Neurofibromatosis Type 1 (NF1) associated glioma
The overarching goal of the registry is to collect baseline and follow-up 1) clinical and 2) imaging data to have a centralized and living repository of information about the adult glioma NF1 patient population.
Time frame: 5 years
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Started Jul 2022 (actual). Primary completion is estimated for Jul 2027, 60 months after the start.
Of 113 non-industry observational studies under Glioma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 104. This study's planned 60 months is below that.
Counting every sponsor, half of 123 studies reached it within 60 months; a quarter within 29 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →